Comparative clinical effectiveness of thrombolytic agents streptokinase versus alteplase versus tenecteplase in the management of ST-segment elevation myocardial infarction: a systematic review and meta-analysis

Zawata Afnan; Tejesh Reddy; Sailesh Pathak; Meher Vani; Vishnu N. Ramani; Nirupama A. Y.; Rajan Shukla

doi:10.18203/2394-6040.ijcmph20263649

Authors

Zawata Afnan Health Technology Assessment India Regional Resource Centre, Indian Institute of Public Health Sciences, Hyderabad, Telangana, India
Tejesh Reddy Public Health Foundation of India, Delhi, India
Sailesh Pathak Health Technology Assessment India Regional Resource Centre, Indian Institute of Public Health Sciences, Hyderabad, Telangana, India
Meher Vani Health Technology Assessment India Regional Resource Centre, Indian Institute of Public Health Sciences, Hyderabad, Telangana, India
Vishnu N. Ramani Health Technology Assessment India Regional Resource Centre, Indian Institute of Public Health Sciences, Hyderabad, Telangana, India
Nirupama A. Y. Health Technology Assessment India Regional Resource Centre, Indian Institute of Public Health Sciences, Hyderabad, Telangana, India
Rajan Shukla Health Technology Assessment India Regional Resource Centre, Indian Institute of Public Health Sciences, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20263649

Keywords:

Thrombolytic agent, Fibrinolytics, Clot lysis, Streptokinase, Alteplase, Tenecteplase

Abstract

ST-segment elevation myocardial infarction (STEMI) remains a leading cause of mortality worldwide, particularly in LMICs where access to primary percutaneous coronary intervention is limited. Thrombolytic therapy continues to be the cornerstone of reperfusion in such settings. This study aimed to assess the clinical effectiveness of fibrinolytic agents Streptokinase (SK), Alteplase (tPA), and Tenecteplase (TNK) in management of STEMI. This SRMA was conducted in accordance with the PRISMA guidelines. A literature search was performed across PubMed, Web of Science, and Embase using predefined keywords. Two independent reviewers screened titles, abstracts, and full texts. Data were extracted in predetermined way and assessed for quality using appropriate critical appraisal tools. Meta-analyses were performed using a random-effects model to compare the clinical outcomes. Total of 12 studies were selected out of 1280, 158 duplicates and 1048 studies were removed based on title and abstract screening, 59 studies were excluded on full text screening. Of all 9 evaluated vessel reperfusion based on TIMI grades, 8 evaluated 30-day mortality, 6 studies reported major bleeding events, 5 reported minor bleeding and 7 reported MACE. Meta-analysis showed significant improvement in reperfusion with fibrinolytic therapy (62.80%; 95% CI: 53.98–71.62%). TNK demonstrated higher reperfusion success and lower 30-day mortality (3.46%; 95% CI: 0.00- 7.85) compared to SK (5.15%; 95% CI 2.27- 8.04%). TNK exhibited the lowest bleeding risk (0.92; 95% CI: 0.03- 1.80%) and favourable MACE outcomes (11.04%, 95% CI: 3.44-18.64). Fibrin-specific thrombolytic i.e. TNK, demonstrate superior efficacy and safety in the management of STEMI.

References

Antman AM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. Circulation. 2004;110:5.

Akbar H, Sharma S. Acute ST-Segment Elevation Myocardial Infarction (STEMI). StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327(7):662-75.

Mitsis A, Gragnano F. Myocardial Infarction with and without ST-segment Elevation: a Contemporary Reappraisal of Similarities and Differences. Curr Cardiol Rev. 2021;17(4):e230421189013.

Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial Infarction: Symptoms and Treatments. Cell Biochem Biophys. 2015;72(3):865-7.

Jamalian M, Roohafza H, Soleimani A, Massoumi G, Mirmohammadsadeghi A, Dorostkar N, et al. Predictors of Mortality for Patients with ST-Elevation Myocardial Infraction after 2-Year Follow-Up: A ST-Elevation Myocardial Infarction Cohort in Isfahan Study. Adv Biomed Res. 2022;11:116.

Guha S, Sethi R, Ray S, Bahl VK, Shanmugasundaram S, Kerkar P, et al. Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India. Indian Heart J. 2017;69(1):S63-97.

Adivitiya, Khasa YP. The evolution of recombinant thrombolytics: Current status and future directions. Bioengineered. 2017;8(4):331-58.

Jinatongthai P, Kongwatcharapong J, Foo CY, Phrommintikul A, Nathisuwan S, Thakkinstian A, et al. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet. 2017;390(10096):747-59.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.

O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425.

Huffman MD, Mohanan PP, Devarajan R, Baldridge AS, Kondal D, Zhao L, et al. Health-Related Quality of Life at 30 Days Among Indian Patients With Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2019;12(2):e004980.

Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76(1):142-54.

NEJM Group - Massachusetts Medical Society. The New England Journal of Medicine. Available at: nejm.org. Accessed on 15 June 2026.

Panduranga P, Al-Zakwani I, Sulaiman K, Al-Habib K, Al Suwaidi J, Al-Motarreb A, et al. Clinical Profile and Mortality of ST-Segment Elevation Myocardial Infarction Patients Receiving Thrombolytic Therapy in the Middle East. Heart Views. 2012;13(2):35-41.

Ayça B, Conkbayır C, Katkat F, Gulsen K, Akin F, Okuyan E, et al. The relationship between grade of ischemia, success of reperfusion, and type of thrombolytic regimen. Med Sci Monit. 2015;21:716-21.

Xavier AA, Chandana R, Sarwar A, Dhanapal CK, Sudarshan S. A Comparative Study of Thrombolytics Used for The Treatment of STEMI in a Research in Pharmacy and Health Sciences. A comparative study of thrombolytics used for the treatment of stemi in a South Indian tertiary care hospital. Res Pharm Health Sci. 2016;2(3):160-2.

Yang HT, Xiu WJ, Zheng YY, Liu F, Gao Y, Ma X, et al. Invasive reperfusion after 12 hours of the symptom onset remains beneficial in patients with ST-segment elevation myocardial infarction: Evidence from a meta-analysis of published data. Cardiol J. 2019;26(4):333-42.

Koh HP, Redzuan A, Mohd S, Jivanraj S, Noel RN, Ross T. The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST ‑ elevation myocardial infarction (STEMI): a propensity ‑ matched retrospective analysis in an Asian population. Int J Clin Pharm. 2022;44(3):641-50.

Singh AK, Sharma R, Saklani NR. A comparative analysis of efficacy of thrombolytics in acute st elevation MI and its variation with circadian rhythm. Cardiology. 2019;8(1):124-7.

Neela B, Gunreddy VR, Chandupatla MR, Eggadi V, Sharvana S, Bandaru B. Safety and Efficacy of Streptokinase, Tenecteplase, and Reteplase in Patients Diagnosed with ST ‑ Elevation Myocardial Infarction: A Comparative Study. J Indian Coll Cardiol. 2020;10(3):134-8.

Shah S, Sukhwani K, Prajapati V, Sahasranam KV. Clinical evaluation of reperfusion in ST elevation myocardial infarction with non-invasive markers following thrombolysis with streptokinase versus tenecteplase. Int J Sci Res. 2021;10(2):35-8.

Koh HP, Md Redzuan A, Mohd Saffian S, Nagarajah JR, Ross NT, Hassan H. The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population. Int J Clin Pharm. 2022;44(3):641-50.

Sahu L, Mohanty NK, Goutam S, Swain TR. Comparative Efficacy between Streptokinase, Tenecteplase and Reteplase in ST Elevated Myocardial Infarction among Patients Attending Tertiary Care Hospital of Odisha. J Clin Diagnost Res. 2022;16(12):FC01-5.

Cochrane library. PRISMA 2020 Checklist. Available at: https://www.prisma-statement.org/ prisma-2020-checklist. Accessed on 15 May 2026.

Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113(2):104-11.